How the Evidence Separates COPD From Asthma

No single test does the job

No single test cleanly separates chronic obstructive pulmonary disease from asthma. The distinction is assembled from three streams of evidence: a clinical history that weighs age of onset, smoking or biomass exposure, and whether breathing symptoms fluctuate or steadily progress; the change in airflow after an inhaled bronchodilator; and spirometry showing whether obstruction fully reverses or persists. The 2025 GOLD report defines COPD by a post-bronchodilator FEV1/FVC ratio below 0.70 that does not normalize, while the 2024 GINA report defines asthma by documented variable expiratory airflow limitation. When both patterns live in the same set of lungs, no threshold resolves them, which is why asthma-COPD overlap is described rather than settled by one number.

Two definitions, built from different evidence

COPD and asthma are defined by opposite emphases. GOLD anchors COPD to airflow obstruction that persists. Its 2025 report keeps the spirometric criterion as a post-bronchodilator FEV1/FVC below 0.70, measured after an inhaled bronchodilator so that the number reflects fixed, not momentary, narrowing. That reading is meant to be paired with the right clinical picture: chronic breathlessness, cough, or sputum, and a relevant exposure such as tobacco, occupational dust, or biomass smoke. The GOLD Science Committee, writing in the European Respiratory Journal in 2025, advised using pre-bronchodilator spirometry to help exclude COPD and post-bronchodilator spirometry to confirm it, and repeating the test on a separate occasion when the ratio lands in the borderline zone between 0.60 and 0.80.

GINA builds asthma from the opposite property: variability. Its 2024 report requires a history of respiratory symptoms (wheeze, shortness of breath, chest tightness, and cough) that vary over time and in intensity, together with confirmed variable expiratory airflow limitation. The defining word is variable. Asthma is a condition whose obstruction comes and goes, which shapes both how it is found and how it hides.

What the history contributes first

Before any tracing is printed, the story does much of the sorting. Asthma tends to begin in childhood or early life, often alongside eczema, allergic rhinitis, or a family history of allergy, and its symptoms flare with triggers such as allergens, exercise, cold air, or viral infections, frequently worse at night or in the early morning. COPD typically surfaces after age 40 in someone with a substantial cumulative exposure, classically many pack-years of tobacco or prolonged biomass smoke, and its breathlessness is more persistent and slowly progressive than episodic. These features are probabilistic, not decisive. A lifelong smoker can have asthma, and a never-smoker can develop fixed obstruction, so history narrows the field without closing it.

Why bronchodilator response stopped being the divider

For years, a large jump in FEV1 after a bronchodilator was treated as a marker of asthma. GINA 2024 still counts a rise in FEV1 of at least 12 percent and at least 200 mL from baseline in adults as evidence of variable airflow limitation, with greater confidence when the increase reaches 15 percent and 400 mL. The problem is that this response is neither exclusive nor reliable across the divide. The GOLD Science Committee noted that acute bronchodilator responsiveness was historically advocated to separate asthma from COPD, yet many people with COPD show excellent flow or volume responses, which gives the test poor discriminative power. Reversibility runs the other way too: because asthma is variable, a patient can produce a normal, non-reversible tracing on the day of testing. GINA therefore advises repeating spirometry when the patient is symptomatic and after withholding bronchodilators, rather than accepting one negative result. A single reversibility number, on its own, sorts almost no one cleanly.

What spirometry can and cannot settle

Spirometry earns its place by answering a narrower question: after a bronchodilator, does obstruction remain? Persistent obstruction, a ratio that stays below 0.70 despite treatment, is the signature of COPD. Airflow that returns to normal points toward asthma. Even here the instrument has limits. The fixed 0.70 threshold overcalls obstruction in some healthy older adults, whose ratio falls with age, and can miss early disease in younger ones, which is why GOLD pairs it with confirmatory testing and, when useful, a lower-limit-of-normal reading. Spirometry tells you whether obstruction is fixed or variable on the day it is measured. It cannot, by itself, tell you which disease process produced it.

Why overlap resists a single test

Some patients carry features of both conditions at once: a smoking history and fixed obstruction alongside marked reversibility, allergy, or eosinophilia. GINA and GOLD have long described this as asthma-COPD overlap, and GINA is explicit that it is not a single disease with its own biology but a practical label for people whose features straddle the two definitions. That is the deeper reason no single test resolves them. The distinguishing variables, age of onset, exposure, reversibility, and symptom pattern, each sit on a continuum, and a person can land in the middle of every one.

The label still carries real weight, and the reason is safety. GINA points to evidence that patients with features of both asthma and COPD face a higher risk of hospitalization or death when treated with long-acting bronchodilators alone, so an inhaled corticosteroid should remain part of their regimen. Classifying such a patient wrongly is not an academic error; it steers treatment. That single fact explains why guidelines keep insisting on the full combination of history, bronchodilator response, and spirometry instead of any one shortcut.

This article is educational and not medical advice; decisions about diagnosing or treating asthma and COPD belong with a qualified clinician who can weigh the whole clinical picture.